UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative ...

UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing Loss

Rincell-1 addresses a multi $Bn global market opportunity where no disease modifying treatments currently exist

UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative ...

Sheffield, July 01, 2025 (GLOBE NEWSWIRE) -

Medicines and Healthcare products Regulatory Agency

The Medicines and Healthcare products Regulatory Agency regulates medicines, medical devices and blood components for transfusion in the UK. MHRA is an executive agency, sponsored by the Department of Health and Social Care .

First-in-human trial for regenerative cell therapy for sensorineural hearing loss approved - Express Pharma

Rinri Therapeutics, a spinout company from the University of Sheffield dedicated to transforming sensorineural hearing loss (SNHL) with regenerative cell therapy, has received approval to begin its first-in-human clinical trial.  The UK’s Medicine and Healthcare products Regulatory Agency (MHRA) approved Rincell-1, a first-in-class otic neural progenitor cell therapy, for the first-in-human Phase I/IIa trial (1). Clinical proof-of-concept data i…

UK Approves First Human Trial of Rinri’s Rincell-1 Cell Therapy for Hearing Loss | Hearing Health & Technology Matters

SHEFFIELD, UNITED KINGDOM — Rinri Therapeutics, a University of Sheffield spinout pioneering regenerative therapies for hearing loss, has received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to begin its first-in-human clinical trial of Rincell-1, a first-in-class otic neural progenitor cell therapy designed to treat sensorineural hearing loss (SNHL). The Phase I/IIa trial, expected to begin imminently, will…

Ocumetics Initiates First-In-Human Study of Accommodating Intraocular Lens

Ocumetics Technology has initiated the first-in-human (FIH) clinical studies for its accommodating intraocular lens, known as the Ocumetics Lens.  Designed to mimic the natural focusing ability of the youthful human eye, the Ocumetics Lens aims to provide patients with seamless, dynamic vision across a full range of distances following cataract surgery. The clinical trial will assess the lens’s safety, effectiveness, and ability to restore near …